Immunohistochemical scores for IL‐6 were significantly increased in cisplatin‐treated animals (P = 0.032 vs. the cancer‐positive group) and decreased in mice treated with the combination therapy (P = 0.029 cisplatin vs. cisplatin plus DMAPT) (Fig. 2P–S). This evidence concerns the gene IL6 and cancer.